Education
About Us
Working with TipRanks
Follow Us
Celcuity (CELC)
NASDAQ:CELC
Earnings Data
Report Date
Nov 17, 2025After Close (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
-1.02Last Year’s EPS
-0.7Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call presented a strong set of highlights with significant clinical trial progress, patent extension, and financial fortification, although it was balanced by increased losses and expenses.Company Guidance
Significant Milestones Achieved
Celcuity reported positive top line data from the PIK3CA wild-type cohort of the Phase III VIKTORIA-1 clinical trial, showing significant improvements in progression-free survival (PFS) for HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer patients. Median PFS for the gedatolisib triplet was 9.3 months with a hazard ratio of 0.24, and 7.4 months for the gedatolisib doublet with a hazard ratio of 0.33.
Phase III VIKTORIA-2 Clinical Trial Progress
The first patient was dosed in the Phase III VIKTORIA-2 trial, evaluating gedatolisib in combination with a CDK4/6 inhibitor and fulvestrant as first-line treatment for HR-positive, HER2-negative advanced breast cancer.
Favorable Preliminary Results from Early-Phase Trials
Preliminary top line results from trials evaluating gedatolisib with darolutamide in prostate cancer and with trastuzumab biosimilar in HER2-positive breast cancer were favorable. The prostate cancer trial showed a 66% 6-month radiographic PFS rate.
Patent Extension for Gedatolisib
Celcuity extended patent exclusivity for gedatolisib into 2042 with a new dosing regimen patent.
Strong Financial Position
Celcuity raised approximately $287 million through public offerings, bringing cash, cash equivalents, and investments to $455 million on a pro forma basis, ensuring funding through 2027.
CELC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CELC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 14, 2025 | $51.89 | $51.79 | -0.19% |
May 14, 2025 | $10.86 | $10.52 | -3.13% |
Mar 31, 2025 | $10.11 | $9.29 | -8.11% |
Nov 14, 2024 | $14.11 | $12.66 | -10.28% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Celcuity (CELC) report earnings?
Celcuity (CELC) is schdueled to report earning on Nov 17, 2025, After Close (Confirmed).
What is Celcuity (CELC) earnings time?
Celcuity (CELC) earnings time is at Nov 17, 2025, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CELC EPS forecast?
CELC EPS forecast for the fiscal quarter 2025 (Q3) is -1.02.